Evidence map›Paper›PMID 35085659›Full record

ArticleThe Journal of infection2022

Disease severity during SARS-COV-2 reinfection: a nationwide study.

Anna A Mensah, Joanne Lacy, Julia Stowe, Giulia Seghezzo, Ruchira Sachdeva, Ruth Simmons, Antoaneta Bukasa, Shennae O'Boyle, Nick Andrews, Mary Ramsay and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 5 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. The Effect of SARS-CoV-2 Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  9. Article
  10. Article
  11. Role of senescent CD4Journal of translational medicine · 2025
    Article
  12. Article
  13. SIRI+Q model with a limited capacity of isolation.Theory in biosciences = Theorie in den Biowissenschaften · 2025
    Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Anna A MensahImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Joanne LacyImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Julia StoweImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Giulia SeghezzoCOVID-19 EpiCell, UK Health Security Agency, London, UK.
Ruchira SachdevaImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Ruth SimmonsImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Antoaneta BukasaImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Shennae O'BoyleImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Nick AndrewsImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Mary RamsayImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
Helen CampbellImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK. Electronic address: Helen.Campbell@ohe.gov.uk.
Kevin BrownImmunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
UK Health Security Agency · GBDepartment of Health and Social Care · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to look at the burden of disease caused by SARS-COV-2 reinfections and identified potential risk factors for disease severity.

methodsWe used national surveillance data to collect information on all SARS-CoV-2 primary infection and suspected reinfection cases between January 2020 until early May 2021. Reinfection cases were positive COVID-19 PCR or antigen test, 90 days after their first COVID-19 positive test. We collected information on case demographics, hospital and ICU admission, immunisation status and if individuals were at risk of complication for COVID-19.

resultsDeaths reported within 28 days of testing positive were 61% (95% confidence interval: 56% to 65%) lower in suspected COVID-19 reinfection than primary infection cases. In the unvaccinated cohort, reinfections were associated with 49% (37% to 58%) lower odds of hospital admission in cases aged 50 to 65 years in the population not identified at risk of complication for COVID-19, and 34% (17% to 48%) in those at risk. ICU admission at reinfection compared to primary infection decreased 76% (55% to 87%). Individuals at risk and those aged below 50 years, who received at least 1 dose of vaccine against COVID-19, were 62% (39% to 74%) and 58% (24% to 77%) less likely to get admitted to hospital at reinfection, respectively.

conclusionPrior SARS-CoV-2 infection was associated with lower odds of dying, and both prior infection and immunisation showed a protective effect against severe disease in selected populations. Older age, sex and underlying comorbidities appeared as principal risk factors for illness severity at reinfection.

fundingPHE/UKHSA.

Indexed as

COVID-19SARS-CoV-2COVID-19 VaccinesHumansReinfectionSeverity of Illness IndexCOVID-19 VaccinesCOVID-19Disease severityImmunisationPrimary infectionReinfectionSARS-CoV-2

Identifiers

PMID35085659
PMCPMC8786677
OpenAlexW4207079197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.